Digoxin indications
Pro Research Analysisby 
Searched over 200M research papers for "digoxin indications"
Digoxin Indications in Heart Failure and Atrial Fibrillation
Digoxin is primarily indicated for two major cardiovascular conditions: heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation (AF), particularly for controlling ventricular rate. In HFrEF, digoxin improves ventricular performance and reduces symptoms by increasing cardiac output and inhibiting the atrioventricular node through its vagomimetic effect. It is also used to decrease hospital readmissions in these patients, especially when combined with other heart failure therapies such as diuretics, ACE inhibitors, beta-blockers, or spironolactone. However, careful monitoring is required due to its narrow therapeutic index and risk of toxicity. Digoxin should not be used in patients with pre-excitation syndromes, as it can precipitate dangerous arrhythmias 1467.
Digoxin Use in Heart Failure with Preserved Ejection Fraction (HFpEF)
The role of digoxin in heart failure with preserved ejection fraction (HFpEF) is less clear. Evidence suggests that digoxin does not significantly affect long-term outcomes such as all-cause mortality or hospitalization rates in HFpEF patients. Therefore, its use in this population is not routinely recommended based on current data .
Digoxin in Non-Cardiac and Emerging Indications
Recent research has explored the potential of digoxin beyond traditional cardiac uses. Laboratory and epidemiological studies have identified digoxin as a possible agent for reducing prostate cancer risk and inhibiting prostate cancer cell growth. Additionally, digoxin has shown promise in enhancing the anticancer effects of drugs like adriamycin in non-small cell lung cancer, while also reducing associated cardiotoxicity. There is also experimental evidence supporting its use in reducing inflammation in osteoarthritis by modulating the inflammatory microenvironment. These findings suggest a growing interest in repurposing digoxin for non-cardiac diseases, although more clinical research is needed before these uses become standard practice 25910.
Digoxin Toxicity and Antidote Indications
Digoxin toxicity is a serious concern due to its narrow therapeutic window. Indications for the use of digoxin-specific antibody fragments (digoxin-Fab) include life-threatening arrhythmias, hyperkalemia, or hemodynamic instability in the presence of elevated digoxin levels. Digoxin-Fab is effective in rapidly reversing toxicity, especially in acute overdose situations, and is considered safe with a low incidence of adverse effects .
Conclusion
Digoxin remains an important medication for specific indications, mainly heart failure with reduced ejection fraction and atrial fibrillation for rate control. Its use in HFpEF is not supported by current evidence. Digoxin toxicity requires prompt recognition and treatment with digoxin-specific antibody fragments in severe cases. Emerging research suggests potential new roles for digoxin in cancer and inflammatory diseases, but these applications are not yet established in clinical practice. Careful patient selection and monitoring are essential to maximize benefits and minimize risks.
Sources and full results
Most relevant research papers on this topic